Global BioAccess Fund

Global BioAccess Fund partners with forward-thinking companies to create new medicines by investing in transformative technologies that address unmet needs in Oncology, I&I (Immunology & Inflammation), Cardiovascular, CNS (Central Nervous System), and rare diseases. They focus on early-stage companies needing capital to support IND (Investigational New Drug) submission and clinical trials. Their team and network of scientific and industry leaders offer broad and deep expertise and resources. With every interaction, they strive to deliver excellence to patients, entrepreneurs, and investors. The fund's investment strategy appears to be centered around identifying and funding companies with novel therapeutics and devices that can address significant unmet medical needs. They provide capital to support crucial stages of drug development like IND submission and early-stage clinical trials, thereby enabling companies to advance their innovative solutions. They aim to accelerate the development of innovative science to create new medicines. Given the portfolio, the fund seems open to investing in varied modalities of therapeutics, including cell therapies, small molecule drugs, and immunotherapies. They look for novel mechanisms and targets within the therapeutic areas they invest. The firm seems willing to invest internationally as reflected by its portfolio companies based in Europe and across the US. The fund's stated commitment to delivering excellence to patients, entrepreneurs, and investors suggests a collaborative and patient-centric approach. They strive to build long-term relationships with their portfolio companies and contribute to the advancement of medical science by backing innovative companies and technologies.

Oncology, I&I, Cardiovascular, CNS, Rare Diseases, Novel Therapeutics, Medical Devices

Core thematic spaces, technologies, and target market segments of interest.